John J. Cush

Telemedicine and Lupus https://t.co/RgfgnMGsZw https://t.co/uQEYLlrlB5

TONIGHT! Tuesday Night Rheumatology: 🔓 Lupus Unlocked: Cutaneous SLE Join us for a discussion of the diagnosis, management, and latest insights into cutaneous manifestations of SLE. Featuring: Dr. Victoria P. Werth Dr. Matilda Nicholas Dr. Anthony Fernandez Dr. Christopher https://t.co/l0QjM9obk2

Is the nosology of CPPD outdated? Pseudogout to chondrocalcinosis? In 2011 EULAR taskforce rec the preferred term "calcium pyrophosphate deposition dz". G-CAN aims to update & standardised terminology for CPPD, requiring change to ICD-10 & adoption by societies https://t.co/wTdc0Tosc6

NEW ACR 2024 POSTER: Phase 3 KEEPsAKE 1 and 2 post hoc analyses of time to first response with an IL-23i View the latest data on time to first efficacy responses and PROs in patients with active PsA. Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/h0Uebdk8vj

Managing CKD in Lupus Nephritis Dr. Hans-Joachim Anders explores how to treat LN patients with chronic kidney disease, balancing disease control and renal preservation. 🎯 Don’t miss these expert pearls. 👉 Full update on RheumNow: https://t.co/frHvcd1xMw #LupusNephritis https://t.co/VedtGaHkMj

Soluble CD13 (sCD13) has pro-inflammatory effects & is elevated in severe COVID-19. sCD13 is chemotactic, angiogenic, & arthritogenic. In COVID-19, sCD13 was assoc w/ sCD13 severity, ethnicity, inflammation markers, NETosis, & vascular injury/thrombosis. https://t.co/dTT9X49DIt

POSTER HALL PRESENTATION: Sponsored by AbbVie Medical Affairs + Health Impact. 🔍Real-world outcomes in patients with RA remaining on first-line TNFi 📽️See Dr. Charles-Schoeman discuss subsequent outcomes in patients who did or did not achieve response at 3 or 6 months https://t.co/2c7lsQJr3V

Full read overview of Discoid Lupus. https://t.co/aXgveR2NwF https://t.co/9JK6CNqedO

A Phase 3 Trial of a JAKi in Patients With Giant Cell Arteritis Coinvestigator Dr. Andrea Rubbert-Roth discusses the results of this Phase 3 trial of a JAKi in GCA. Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/jzBBhNFe46 https://t.co/UwOv0JRKKK

Risk Factors for Knee Osteoarthritis New research from the University of Sydney reveals that obesity, having a knee injury and occupational risks such as shift work and lifting heavy loads are primary causes of knee osteoarthritis. https://t.co/Kc686Zc8Xa https://t.co/PtyLU6jBkp

Lupus Unlocked: Journal Club In this first webinar of RheumNow's Lupus Unlocked campaign, Journal Club discussed two articles: Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis. Furie R, et al. NEJM. 2025 Feb 7. doi: 10.1056 Efficacy and safety of voclosporin https://t.co/OYv5J8VpRB

Betw 2005 -2021, there was a substantial increase in HCQ use, but only modest steroid (GC) reductions. Swedish cohort study of 3891 SLE pts - over 5 yrs GC decr from 68% - 54% to 46%. HCQ increased by 29% over 5 years. https://t.co/sI7JWq3AGk https://t.co/RBUMcl8uGz

Emulation trials in SLE: Real or Fake? Recently a landmark paper was published in A&R studying the results of an emulation trial. My colleagues and I were able to write an editorial on this paper and describe emulation trials. https://t.co/0ulYG5xz0J https://t.co/8oj8UDV9Dd

NEW POSTER: 4-Year maintenance of an IL-23i response in PsA View maintenance of ACR20/50/70, MDA, PASI90 responses, and meaningful pain reduction through ~4 years in the KEEPsAKE 1 and 2 studies. Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/qq5Z4SgKv5 https://t.co/osWflKgdV1

New Steroid Rules in Lupus? Let’s Talk. Dr. Michelle Petri breaks down the latest strategies to minimize steroid exposure while managing disease activity in lupus patients. 💡 Smarter steroid use = better outcomes. 👉 Watch now on RheumNow: https://t.co/vbjrXAlixz #Lupus https://t.co/04CjTkCqMJ

Telitacicept, recombinant fusion protein targeting BLyS & APRIL, studied in 41 Chinese SLE pts (added to standard Rx) showed mean improvements in SLEDAI-2K (10.0 to 6.25 @12 wks & 4.2 @24 wks;p<.001), daily prednisone (21 mg to 9.8mg) & proteinuria (2.8 gr to 1.3 gr/day) https://t.co/KHMWPeq79x